Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFOP |
Texto Completo: | http://www.repositorio.ufop.br/jspui/handle/123456789/14035 |
Resumo: | The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best. |
id |
UFOP_ea94c55a939ce34ea598622c16213f5e |
---|---|
oai_identifier_str |
oai:repositorio.ufop.br:123456789/14035 |
network_acronym_str |
UFOP |
network_name_str |
Repositório Institucional da UFOP |
repository_id_str |
3233 |
spelling |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.Resolution of inflammationAllergic lung inflammationLipopolysaccharide(LPS)The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.2021-11-24T20:15:57Z2021-11-24T20:15:57Z2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfMAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021.1663-9812http://www.repositorio.ufop.br/jspui/handle/123456789/14035 https://doi.org/10.3389/fphar.2021.557962This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Source: The article PDF.info:eu-repo/semantics/openAccessMagalhães, Giselle SantosGregório, Juliana FabianaRibeiro, Arthur Tonani Pereira CançadoBaroni, Isis FelippeVasconcellos, Ana Victoria de OliveiraNakashima, Gabriela PansanatoOliveira, Isabel Fusaro AguiarMatos, Natália Alves deCastro, Thalles de FreitasBezerra, Frank SilvaSinisterra, Ruben DarioPinho, VanessaTeixeira, Mauro MartinsSantos, Robson Augusto Souza dosMachado, Maria da Glória RodriguesSantos, Maria José Campagnole dosengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOP2021-11-24T20:16:06Zoai:repositorio.ufop.br:123456789/14035Repositório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332021-11-24T20:16:06Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false |
dc.title.none.fl_str_mv |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
title |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
spellingShingle |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Magalhães, Giselle Santos Resolution of inflammation Allergic lung inflammation Lipopolysaccharide(LPS) |
title_short |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
title_full |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
title_fullStr |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
title_full_unstemmed |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
title_sort |
Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. |
author |
Magalhães, Giselle Santos |
author_facet |
Magalhães, Giselle Santos Gregório, Juliana Fabiana Ribeiro, Arthur Tonani Pereira Cançado Baroni, Isis Felippe Vasconcellos, Ana Victoria de Oliveira Nakashima, Gabriela Pansanato Oliveira, Isabel Fusaro Aguiar Matos, Natália Alves de Castro, Thalles de Freitas Bezerra, Frank Silva Sinisterra, Ruben Dario Pinho, Vanessa Teixeira, Mauro Martins Santos, Robson Augusto Souza dos Machado, Maria da Glória Rodrigues Santos, Maria José Campagnole dos |
author_role |
author |
author2 |
Gregório, Juliana Fabiana Ribeiro, Arthur Tonani Pereira Cançado Baroni, Isis Felippe Vasconcellos, Ana Victoria de Oliveira Nakashima, Gabriela Pansanato Oliveira, Isabel Fusaro Aguiar Matos, Natália Alves de Castro, Thalles de Freitas Bezerra, Frank Silva Sinisterra, Ruben Dario Pinho, Vanessa Teixeira, Mauro Martins Santos, Robson Augusto Souza dos Machado, Maria da Glória Rodrigues Santos, Maria José Campagnole dos |
author2_role |
author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Magalhães, Giselle Santos Gregório, Juliana Fabiana Ribeiro, Arthur Tonani Pereira Cançado Baroni, Isis Felippe Vasconcellos, Ana Victoria de Oliveira Nakashima, Gabriela Pansanato Oliveira, Isabel Fusaro Aguiar Matos, Natália Alves de Castro, Thalles de Freitas Bezerra, Frank Silva Sinisterra, Ruben Dario Pinho, Vanessa Teixeira, Mauro Martins Santos, Robson Augusto Souza dos Machado, Maria da Glória Rodrigues Santos, Maria José Campagnole dos |
dc.subject.por.fl_str_mv |
Resolution of inflammation Allergic lung inflammation Lipopolysaccharide(LPS) |
topic |
Resolution of inflammation Allergic lung inflammation Lipopolysaccharide(LPS) |
description |
The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-24T20:15:57Z 2021-11-24T20:15:57Z 2021 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
MAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021. 1663-9812 http://www.repositorio.ufop.br/jspui/handle/123456789/14035 https://doi.org/10.3389/fphar.2021.557962 |
identifier_str_mv |
MAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021. 1663-9812 https://doi.org/10.3389/fphar.2021.557962 |
url |
http://www.repositorio.ufop.br/jspui/handle/123456789/14035 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFOP instname:Universidade Federal de Ouro Preto (UFOP) instacron:UFOP |
instname_str |
Universidade Federal de Ouro Preto (UFOP) |
instacron_str |
UFOP |
institution |
UFOP |
reponame_str |
Repositório Institucional da UFOP |
collection |
Repositório Institucional da UFOP |
repository.name.fl_str_mv |
Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP) |
repository.mail.fl_str_mv |
repositorio@ufop.edu.br |
_version_ |
1813002816830046208 |